Roofeh, D;
Distler, O;
Allanore, Y;
Denton, CP;
Khanna, D;
(2020)
Treatment of systemic sclerosis associated ILD: Lessons from clinical trials.
Journal of Scleroderma and Related Disorders
, 5
(2 Suppl)
pp. 61-71.
10.1177/2397198320903208.
Preview |
Text
Roofeh JSRD for UCL upload 2021.pdf - Accepted Version Download (369kB) | Preview |
Abstract
Systemic sclerosis–associated interstitial lung disease remains a leading cause of mortality. Despite decades of clinical trials, the treatment effects of disease modifying anti-rheumatic drugs continue to be modest and there remains a great need for therapies that attenuate and hopefully ameliorate parenchymal lung disease. In this review, we highlight the key clinical trials that have shaped the management strategies employed by the authors, providing their strength of recommendation based on level of evidence. We also review lessons learned in more recent years, suggesting a benefit in targeting patients with subclinical interstitial lung disease with high risk for progression early in the disease course, as well as the benefit seen in a large clinical trial leading to the first Food and Drug Administration–approved treatment for systemic sclerosis–associated interstitial lung disease. These lessons come in a context of heterogeneity of patient populations and response to therapy, as well as the inherent constraints of time-limited studies to detect meaningful outcomes for patients.
| Type: | Article |
|---|---|
| Title: | Treatment of systemic sclerosis associated ILD: Lessons from clinical trials |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1177/2397198320903208 |
| Publisher version: | https://doi.org/10.1177/2397198320903208 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Systemic sclerosis, interstitial lung disease, clinical trials, management, treatment |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10129567 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
